104 related articles for article (PubMed ID: 6441755)
1. 4-Demethoxydaunorubicin (idarubicin) in refractory or relapsed acute leukemias.
Carella AM; Santini G; Martinengo M; Marmont AM
Haematologica; 1984; 69(6):767-8. PubMed ID: 6441755
[No Abstract] [Full Text] [Related]
2. 4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.
Carella AM; Santini G; Martinengo M; Giordano D; Nati S; Congiu A; Cerri R; Risso M; Damasio E; Rossi E
Cancer; 1985 Apr; 55(7):1452-4. PubMed ID: 3856461
[TBL] [Abstract][Full Text] [Related]
3. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.
Daghestani AN; Arlin ZA; Leyland-Jones B; Gee TS; Kempin SJ; Mertelsmann R; Budman D; Schulman P; Baratz R; Williams L
Cancer Res; 1985 Mar; 45(3):1408-12. PubMed ID: 3855696
[TBL] [Abstract][Full Text] [Related]
4. Effect of 4-demethoxydaunorubicin (4-DMDR) in chronic myeloid leukemia in blastic transformation and relapsed acute leukemias.
Bandini G; Comotti B; Scapoli G; Leoni F; Di Prisco U; Mangoni L; Battista R; Tura S
Haematologica; 1985; 70(2):155-9. PubMed ID: 3924779
[No Abstract] [Full Text] [Related]
5. Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia.
Harousseau JL; Hurteloup P; Reiffers J; Rigal-Huguet F; Hayat M; Dufour P; Le Prise PY; Monconduit M; Jaubert J; Carcassonne Y
Cancer Treat Rep; 1987 Oct; 71(10):991-2. PubMed ID: 3477319
[No Abstract] [Full Text] [Related]
6. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.
Pui CH; de Graaf SS; Dow LW; Rodman JH; Evans WE; Alpert BS; Murphy SB
Cancer Res; 1988 Sep; 48(18):5348-52. PubMed ID: 3165708
[TBL] [Abstract][Full Text] [Related]
7. Preliminary results in secondary acute non-lymphocytic leukemia (ANLL) treated with Idarubicin.
Parmentier C; Finaud M; Schlumberger M; Morardet N; Berger R; Bayle C; Carde P; Hurteloup P; Hayat M
Nouv Rev Fr Hematol (1978); 1985; 27(6):393-5. PubMed ID: 3867854
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of Idarubicin (4-demethoxydaunorubicin) in adult acute leukemia.
Hayat M; Hurteloup P; Parmentier C; Carde P; Pico JO; Schlumberger M; Chahine G; Kamioner D
Invest New Drugs; 1984; 2(4):375-9. PubMed ID: 6595242
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic activity of 4-demethoxydauno-rubicin (idarubicin) in adult acute leukemia.
Lambertenghi-Deliliers G; Pogliani E; Maiolo AT; Pacciarini MA; Polli EE
Tumori; 1983 Dec; 69(6):515-9. PubMed ID: 6582678
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
Ganzina F; Pacciarini MA; Di Pietro N
Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
[TBL] [Abstract][Full Text] [Related]
11. Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells.
Fukushima T; Ueda T; Uchida M; Nakamura T
Int J Hematol; 1993 Apr; 57(2):121-30. PubMed ID: 8494991
[TBL] [Abstract][Full Text] [Related]
12. Antileukemic activity of 4-demethoxydaunorubicin in mice.
Casazza AM; Pratesi G; Giuliani F; Di Marco A
Tumori; 1980 Oct; 66(5):549-64. PubMed ID: 6936969
[TBL] [Abstract][Full Text] [Related]
13. Idarubicin alone or in combination with cytarabine and etoposide (3 + 3 + 5 protocol) in acute non-lymphoblastic leukaemia.
Carella AM; Santini G; Giordano D; Frassoni F; Martinengo M; Congiu A; Nati S; Risso M; Cerri R; Marmont A
Leuk Res; 1985; 9(5):631. PubMed ID: 3859711
[No Abstract] [Full Text] [Related]
14. Phase II trial of 4-demethoxydaunorubicin in advanced colorectal carcinoma.
Harper HD; Kemeny NE; Ahmed T; Cheng E; Arena F; Sordillo P; Faye L
Cancer Treat Rep; 1984 Apr; 68(4):689-90. PubMed ID: 6585273
[No Abstract] [Full Text] [Related]
15. Phase II trial of 4-demethoxydaunorubicin in patients with advanced malignant melanoma.
Stanton G; Casper ES; Friedman B
Cancer Treat Rep; 1985; 69(7-8):915-6. PubMed ID: 3860298
[No Abstract] [Full Text] [Related]
16. Phase-I trial of 4-demethoxydaunorubicin in acute leukaemias.
Sessa C; Tschopp L; Fopp M; Cavalli F
Invest New Drugs; 1985; 3(4):357-9. PubMed ID: 3866755
[TBL] [Abstract][Full Text] [Related]
17. Anthracyclines in the treatment of acute nonlymphocytic leukemias.
Boiron M; Jacquillat C; Marty M; Weil M; Gisselbrecht C
Cancer Treat Rep; 1981; 65 Suppl 4():73-6. PubMed ID: 6955013
[No Abstract] [Full Text] [Related]
18. Phase II study of 4-demethoxydaunorubicin in advanced ovarian carcinoma.
Hakes TB; Daghestani AN; Dougherty JB; Weiselberg L; Raymond V
Cancer Treat Rep; 1985 May; 69(5):559-60. PubMed ID: 3859369
[No Abstract] [Full Text] [Related]
19. Clinical evaluation of 4-demethoxydaunorubicin in patients with advanced malignant lymphoma.
Coonley CJ; Warrell RP; Straus DJ; Young CW
Cancer Treat Rep; 1983 Oct; 67(10):949-50. PubMed ID: 6578873
[No Abstract] [Full Text] [Related]
20. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
